Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epclusa in HCV-negative recipients of HCV-positive donor lungs
NCT03377478Phase 1Completed
- Start
- Jul 2019
- Primary completion
- Sep 2021
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of velpatasvir in hepatitis C (HCV). Primary endpoints: Hepatitis C Virus Viremia at 2 years and Hepatitis C Virus Seroconversion at 2 years. Started Jul 2019; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03377478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377478.